ABCG2 is associated with HER-2 Expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma

Diagnostic Pathology

Genyin Zhou¹  Peng Gao¹  Yan Wang¹  Zhiyan Liu¹  Shujun Xia¹  Peng Su¹  Lei Xiang¹ 

[1] Department of Pathology, Shandong University School of Medicine, 44, Wenhua Xi Road, Ji'nan, Shandong Province, P.R.China

关键词: Tissue microarray;    Immunohistochemistry;    Breast invasive ductal cancer;    Correlation;    Clinical stage;    Lymph node metastasis;    Her-2;    ABCG2(BCRP);   

Others  :  808241
DOI  :  10.1186/1746-1596-6-90

 received in 2011-08-23, accepted in 2011-09-27,  发布年份 2011

【 摘 要 】

Background

ABCG2 is an ABC transporter. It has been demonstrated that endogenous ABCG2 expression in certain cancers is a possible reflection of the differentiated phenotype of the cell of origin and likely contributes to intrinsic drug resistance. But little is known about the contribution of ABCG2 to the drug resistance and the clinicopathological characteristics in breast cancer. In the present study, we investigated the expression of ABCG2 and the correlations between ABCG2 expression and patients' clinicopathological and biological characteristics.

Methods

Immunohistochemistry was employed on the tissue microarray paraffin sections of surgically removed samples from 196 breast cancer patients with clinicopathological data.

Results

The results showed that ABCG2 was expressed in different intensities and distributions in the tumor cells of the breast invasive ductal carcinoma. A positive stain for ABCG2 was defined as a brown stain observed in the cytoplasm and cytomembrane. A statistically significant correlation was demonstrated between ABCG2 expression and HER-2 expression (p = 0.001), lymph node metastasis (p = 0.049), and clinical stage (p = 0.015) respectively.

Conclusion

ABCG2 correlated with Her-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. It could be a novel potential bio-marker which can predict biological behavior, clinical progression, prognosis and chemotherapy effectiveness.

【 授权许可】

   
2011 Xiang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bombonati A, Sgroi DC: The molecular pathology of breast cancer progression. J Pathol 2011, 223:307-317.
• [2]Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide version 1.0. IARC Cancer Base No. 5. Lyon: IARC Press; 2001.
• [3]Barrett SV: Breast cancer. J R Coll Physicians Edinb 2010, 40:335-338.
• [4]Moulder S: Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl) 2010, 6:821-30.
• [5]Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer 2002, 2:48-58.
• [6]Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE: ABCG2: A perspective. Advanced Drug Delivery Reviews 2009, 61:3-13.
• [7]Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y: Expression of multidrug resistance-related transporters in human breast carcinoma. Japanese Journal of Cancer Research 2001, 92:452-458.
• [8]Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH, van De Vijver MJ: Expression of the breast cancer resistance protein in breast cancer. Clinical Cancer Research 2002, 8:1068-1074.
• [9]Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clinical Cancer Research 2003, 9:827-836.
• [10]Tavassoli FA, Devilee P: Intraductal proliferative lesions. Pathology and genetics of tumors of the breast and female genetic organs. Lyon: International Agency for Research on Cancer (IARC) Press; 2003.
• [11]Greene FL, Page DL, Fleming ID: Breast Cancer in AJCC Cancer Staging Handbook. TNM Classification of Malignant Tumors. 6th edition. New York: Springer Verlag; 2002.
• [12]Elston CW, Ellis IO: experience from a large study with long-term follow-up. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Histopathology 1991, 19:403-410.
• [13]Cutler SJ, Black MM, Mork T, Harvei S, Freeman C: Further observations on prognostic factors in cancer of the female breast. Cancer 1969, 24:653-667.
• [14]Su P, Zhang Q, Yang Q: Research Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue. Diagnostic Pathology 2010, 5:38. BioMed Central Full Text
• [15]Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Research 1998, 58:5337-5339.
• [16]Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bate SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Research 1999, 59:8-13.
• [17]Knutsen T, Rao VK, Ried T, Mickley L, Schneider E, Miyake K, Ghadimi BM, Padilla-Nash H, Pack S, Greenberger L, Cowan K, Dean M, Fojo T, Bate S: Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes & Cancer 2000, 27:110-116.
• [18]Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD: Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochimica et Biophysica Acta 2001, 1520:234-241.
• [19]Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Research 2001, 61:3458-3464.
• [20]Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR, Izquierdo MA: Frequent expression of the multi-drug resistance associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002, 198:213-219.
• [21]King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976.
• [22]Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
• [23]Gutierrez C, Schiff R: HER2: Biology, Detection, and Clinical Implications. Arch Pathol Lab Med 2011, 135:55-62.
• [24]Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
• [25]Qiao M, Sheng S, Pardee AB: Metastasis and AKT activation. Cell Cycle 2008, 7:2991-2996.
• [26]Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT: Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 2004, 64:1247-1251.
• [27]Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004, 279:24218-24225.
• [28]Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, Jeney V, Ozvegy-Laczka C, Szanto A, Barta E, Balla J, Sarkadi B, Nagy L: Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 2006, 281:23812-23823.
• [29]Imai Y, Ishikawa E, Asada S, Sugimoto Y: Estrogen-mediated postranscriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005, 65:596-604.
• [30]Zhang Y, Zhou G, Wang H, Zhang X, Wei F, Cai Y, Yin D: Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ER alpha-positive MCF-7 breast cancer cells. Oncology 2006, 71:446-455.
• [31]Wang H, Unadkat JD, Mao Q: Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res 2008, 25:444-452.
• [32]Hartz AM, Madole EK, Miller DS, Bauer B: Estrogen Receptorβ Signaling through Phosphatase and Tensin Homolog/Phosphoinositide 3-Kinase/Akt/Glycogen Synthase Kinase 3 Down-Regulates Blood-Brain Barrier Breast Cancer Resistance Protein. JPET 2010, 334:467-476.
• [33]Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.